Usona Institute Overview and Psilocybin FDA Approval Status - EntheoGeneration 2019
Channel: EntheoGeneration
Date: 2019-12-03

Bill Linton provides an overview of Usona Institute and philanthropic support for its current and future programs. Poncho Meissenheimer, Ph.D., covers Usona Institute's psilocybin clinical program, and Alex Sherwood, Ph.D., outlines the chemistry program’s role in the creation of new molecules for the global research community.
 
Bill Linton is the Founder and Co-Executive Director of Usona Institute, and President of the Board of Directors. He also founded and is CEO of Promega Corporation. Poncho Meisenheimer, Ph.D., serves on the Scientific Advisory Board for Usona Institute and for the Chemical Probes Portal, and has led chemistry research programs in drug candidates to enable psychedelic-assisted therapies. Alex Sherwood, Ph.D., is a medicinal chemist for the non-profit Usona Institute where he focuses on the synthesis and exploration of new and known psychedelic compounds to better understand their mechanism of action and potential uses.
 
Hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS) and the Zendo Project, the EntheoGeneration speaker series launched at Burning Man 2019. A wide variety of educational presentations were held from Wednesday, August 28, 2019, through Saturday, August 31, 2019, featuring topics that explore the latest research and healing opportunities for humanity, how to address issues of inclusion and access, strategies to protect indigenous plant medicine traditions and more, from the brightest leaders active in the field today.

EntheoGeneration:
https://zendoproject.org/entheogeneration/
 
The Multidisciplinary Association for Psychedelic Studies (MAPS):
https://maps.org
 
The Zendo Project - Psychedelic Peer Support:
https://zendoproject.org